Prepared by high salt extraction of HeLa nuclei (human cervical cancer cell line), this extract is a rich source of HDAC activity, useful for inhibitor screening or immunoprecipitation of HDAC containing complexes. Typically, 0.5µl or less per well is sufficient for assay with the HDAC FLUOR DE LYS® fluorometric activity assay (Prod. No. BML-AK500).
Product Details
| Formulation: | Liquid. In 0.1M KCl, 20mM HEPES/NaOH, pH 7.9, 20% (v/v) glycerol, 0.2mM EDTA, 0.5mM DTT, 0.5mM PMSF. |
| |
| Shipping: | Shipped on Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Measuring Histone Deacetylase Inhibition in the Brain: D.S. Reddy, et al.; Curr. Protoc. Pharmacol.
81, e41 (2018),
Abstract;
Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents: D.T. Hieu, et al.; Bioorg. Chem.
76, 258 (2017),
Abstract;
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity: R. Cincinelli, et al.; Eur. J. Med. Chem.
112, 99 (2016),
Application(s): Compounds were tested for HDAC inhibition on HeLa nuclear extract,
Abstract;
Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors: W.H. Huang, et al.; Eur. J. Med. Chem.
46, 4042 (2011),
Abstract;
Related Products
